RGEN - Repligen Operating Profitability

RGEN (Repligen Corp) - company brandmark

High regulatory barriers and the cost of process recertification solidify Repligen Corporation (RGEN) positions in bioprocessing. Effective outsourcing of standard components combined with full patent ownership eliminates technological dependence. Proprietary sterile manufacturing plants in Europe and the US guarantee supply stability. The operating margin trajectory reflects the dynamics of core business profits, where 8.60 serves as the current metric level.

repligen.com (RGEN): Operating Profit Rate from 07/04/2022 to 11/19/2026

Financial and market metric breakdowns for Repligen Corporation (RGEN)

- price and consensus price forecast:
- market capitalization statistics:
Initial company analysis:RGEN, repligen.com
Brand item of Repligen Inc.

To objectively assess the efficiency of Repligen Corporation (RGEN), it is critical for investors to analyze the ratio of operating profit to revenue before interest and taxes. The operating margin trend reflects the synergy between robotic manufacturing and R&D expenditures, where the high stability of this trend confirms the quality of capital and the resilience of the issuer's business model.

Competitors of Repligen Corporation

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RNA - Operating Return on Sales|crisprtx.com - Operating Sales Margin|Operating Profit Rate WGS|RARE - Operating Profitability|Beam Tx (BEAM) - Operating Sales Margin|SRPT (Sarepta Therapeutics Inc) - Operating Sales Margin|TWST: Operating Profit Ratio|TXG (10xgenomics.com) - Operating Margin|NTLA (Intellia Therapeutics, Inc.) - Operating Profit Ratio|Operating Profitability Stoke Corp (STOK)|Profitability of Operations BioLife|Operating Margin WVE (Wave Life Sciences Ltd)|MAZE: Return on Sales by Operating Profit|Sionna Therapeutics, Inc. - Operating Margin|Operating Profit Rate PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Operating Sales Margin|QURE - Profitability of Operations|MGTX (MeiraGTx Corp) - Operating Margin|Operating Return on Sales REGENXBIO Inc. RGNX|Operating Profitability Solid Biosciences (SLDB)|Ocugen Corp - Return on Sales by Operating Profit|Operating Profitability Pacific Biosciences PACB|Operating Profit Ratio BNTC (Benitec)|Design Corp - Operating Margin|Rocket Pharmaceuticals - Operating Profit Ratio|Return on Sales by Operating Profit 4D Molecular Therapeutics, Inc.|Operating Return on Sales Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Operating Margin|Operating Return on Sales Editas EDIT|Operating Margin SLN|ProQR Therapeutics - Return on Sales by Operating Profit|Operating Margin CDXS (Codexis, Inc.)|SGMO: Return on Sales by Operating Profit|Nautilus Biotechnology - Operating Margin|Operating Profit Rate MGX (Metagenomi, Inc)|DTIL: Operating Margin|GBIO: Operating Profit Ratio|Operating Profitability Boundless Bio Inc.|Operating Sales Margin Exicure (XCUR)|Operating Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operating Profit Rate|Mustang Bio, Inc. - Operating Sales Margin|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability